Drug application
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) (DOXORUBICIN HYDROCHLORIDE)
Drugs@FDA ANDA 212219 · BAXTER HLTHCARE CORP
Key facts
| Drug name | DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) |
|---|---|
| Active ingredients | DOXORUBICIN HYDROCHLORIDE |
| Application type | ANDA |
| Application number | 212219 |
| Company | BAXTER HLTHCARE CORP |
| Dosage forms | INJECTABLE, LIPOSOMAL, INJECTION |
| Strength | 20MG/10ML (2MG/ML) |
| Marketing status | Prescription |
| TE codes | AB |
| Reference listed drug | No |
| Latest submission status date | Oct 19, 2022 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.